Carolyn O. Dirain
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Carolyn O. Dirain has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Patrick J. Antonelli
University of Florida
5 shared publications Abhisheak Sharma
Department of Pharmaceutics University of Florida Gainesville Florida USA
1 shared publication- Arunima Vijay
Affiliation Department of Otolaryngology, University of Florida College of Medicine, Gainesville, Florida, United States of America
1 shared publication - Bianca Maria Festa
Otorhinolaryngology Unit IRCCS Humanitas Research Hospital Milan Italy
1 shared publication Brian Hughley
Department of Otolaryngology-Head and Neck Surgery, University of Florida, Gainesville, FL, USA
1 shared publication- Chetan Bettegowda
Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD
1 shared publication
Latest Publications
- Open Access
- 12 January 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 8 (1)
A novel approach to reverse Warburg metabolism in patients with recurrent glioblastoma: A phase II pharmacodynamic study of dichloroacetate
Background: Glioblastomas are characterized by the Warburg effect, driven by upregulation of pyruvate dehydrogenase kinase (PDK), which inhibits pyruvate dehydrogenase complex (PDC), leading to lactate accumulation. Dichloroacetate (DCA) is a potent and safe PDK inhibitor that crosses the blood-brain barrier, reverses Warburg metabolism, and reduces lactate levels. Methods: This trial (RO1FD007271) evaluated the pharmacodynamics and pharmacokinetics of oral DCA in recurrent glioblastoma patients requiring surgical debulking. The primary endpoint was decreased PDC phosphorylation (p-PDHA1) in resected tumors. Patients received either 1 week of DCA or no DCA prior to surgery. All patients received DCA postoperatively. Enhancing and non-enhancing tumor tissue, and serial plasma DCA and lactate levels were analyzed. Results: 37 patients were enrolled (median age = 60 years). In DCA-treated patients, the contrast-enhancing tumor had lower p-PDHA1, PDK4, HIF1-α, VEGF-α, and PGK1 expression (all P < .05) than non-DCA-treated patients. In non-enhancing tumors, p-PDHA1 and PDK 1-3 expression were not different, but PDK4, PCNA, and PGK1 levels were reduced, and ERK1/2 was increased in DCA-treated patients (all P ≤ .01). At surgery, DCA-treated patients had lower plasma lactate (P = .004) than untreated patients. Postoperatively when all patients received DCA, plasma lactate fell dramatically (P < .001). DCA was well-tolerated but did not delay tumor recurrence. Conclusions: In recurrent glioblastomas, DCA was safe, well-tolerated, and promoted aerobic respiration. It reduced markers of tumor cell proliferation and lowered plasma lactate. Although no clinical benefit was noted, further studies of combination therapy are indicated, given the known association between poor cancer outcomes and elevated PDK expression and lactate levels.
- 12 January 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 8 (1)
Open AccessA novel approach to reverse Warburg metabolism in patients with recurrent glioblastoma: A phase II pharmacodynamic study of dichloroacetate
Background: Glioblastomas are characterized by the Warburg effect, driven by upregulation of pyruvate dehydrogenase kinase (PDK), which inhibits pyruvate dehydrogenase complex (PDC), leading to lactate accumulation. Dichloroacetate (DCA) is a potent and safe PDK inhibitor that crosses the blood-brain barrier, reverses Warburg metabolism, and reduces lactate levels. Methods: This trial (RO1FD007271) evaluated the pharmacodynamics and pharmacokinetics of oral DCA in recurrent glioblastoma patients requiring surgical debulking. The primary endpoint was decreased PDC phosphorylation (p-PDHA1) in resected tumors. Patients received either 1 week of DCA or no DCA prior to surgery. All patients received DCA postoperatively. Enhancing and non-enhancing tumor tissue, and serial plasma DCA and lactate levels were analyzed. Results: 37 patients were enrolled (median age = 60 years). In DCA-treated patients, the contrast-enhancing tumor had lower p-PDHA1, PDK4, HIF1-α, VEGF-α, and PGK1 expression (all P < .05) than non-DCA-treated patients. In non-enhancing tumors, p-PDHA1 and PDK 1-3 expression were not different, but PDK4, PCNA, and PGK1 levels were reduced, and ERK1/2 was increased in DCA-treated patients (all P ≤ .01). At surgery, DCA-treated patients had lower plasma lactate (P = .004) than untreated patients. Postoperatively when all patients received DCA, plasma lactate fell dramatically (P < .001). DCA was well-tolerated but did not delay tumor recurrence. Conclusions: In recurrent glioblastomas, DCA was safe, well-tolerated, and promoted aerobic respiration. It reduced markers of tumor cell proliferation and lowered plasma lactate. Although no clinical benefit was noted, further studies of combination therapy are indicated, given the known association between poor cancer outcomes and elevated PDK expression and lactate levels.
- Open Access
- 26 March 2024
- Published by Wiley in Otolaryngology–Head and Neck Surgery
- Vol. 171 (2) , 400-407
Microbiome and Otic Quinolone Levels Following Tympanoplasty Assessed by Gelatin Sponge Analysis
Objective: To determine if absorbable gelatin sponge (AGS) can be used to assess the posttympanoplasty microbiome and otic antibiotic exposure.Study Design: Prospective.Setting: Tertiary hospital.Methods: Patients undergoing tympanoplasty were prospectively enrolled. Intraoperatively, AGS was applied to the medial ear canal/tympanic membrane (TM) for 1 minute after canal incision, then saved for analysis. Ear canals were packed with AGS at the end of surgery. Otic ofloxacin was administered until the first postoperative visit, when AGS was collected. Microbial presence was assessed by culture. Ofloxacin levels were assessed by liquid‐chromatography mass‐spectrometry.Results: Fifty‐three patients were included. AGS was collected in 92.9% of patients seen within 21 days compared to 70.8% of those seen at 22 to 35 days. At surgery, AGS yielded bacteria and fungi in 81% and 11%, respectively, including Staphylococcus species (55%) and Pseudomonas species (25%). Postoperatively, AGS yielded bacteria in 71% and fungi in 21% at the meatus, (staphylococci 57% and pseudomonas 25%). TM samples yielded bacteria in 69%, fungi in 6%, staphylococci in 53%, and pseudomonas in 19%. Ofloxacin concentration at the meatus was 248 μg/mL (95% confidence interval [CI]: 119‐377) and at the TM was 126 μg/mL (95% CI: 58‐194). Ofloxacin‐resistant colonies were found in 75% of patients.Conclusion: Analysis of AGS is a viable technique for noninvasively studying healing metrics posttympanoplasty, including the microbiome and otic antibiotic exposure. Despite exposure to a high concentration of quinolones, the tympanoplasty wound is far from sterile, which may impact healing outcomes.
- 26 March 2024
- Published by Wiley in Otolaryngology–Head and Neck Surgery
- Vol. 171 (2) , 400-407
Open AccessMicrobiome and Otic Quinolone Levels Following Tympanoplasty Assessed by Gelatin Sponge Analysis
Objective: To determine if absorbable gelatin sponge (AGS) can be used to assess the posttympanoplasty microbiome and otic antibiotic exposure.Study Design: Prospective.Setting: Tertiary hospital.Methods: Patients undergoing tympanoplasty were prospectively enrolled. Intraoperatively, AGS was applied to the medial ear canal/tympanic membrane (TM) for 1 minute after canal incision, then saved for analysis. Ear canals were packed with AGS at the end of surgery. Otic ofloxacin was administered until the first postoperative visit, when AGS was collected. Microbial presence was assessed by culture. Ofloxacin levels were assessed by liquid‐chromatography mass‐spectrometry.Results: Fifty‐three patients were included. AGS was collected in 92.9% of patients seen within 21 days compared to 70.8% of those seen at 22 to 35 days. At surgery, AGS yielded bacteria and fungi in 81% and 11%, respectively, including Staphylococcus species (55%) and Pseudomonas species (25%). Postoperatively, AGS yielded bacteria in 71% and fungi in 21% at the meatus, (staphylococci 57% and pseudomonas 25%). TM samples yielded bacteria in 69%, fungi in 6%, staphylococci in 53%, and pseudomonas in 19%. Ofloxacin concentration at the meatus was 248 μg/mL (95% confidence interval [CI]: 119‐377) and at the TM was 126 μg/mL (95% CI: 58‐194). Ofloxacin‐resistant colonies were found in 75% of patients.Conclusion: Analysis of AGS is a viable technique for noninvasively studying healing metrics posttympanoplasty, including the microbiome and otic antibiotic exposure. Despite exposure to a high concentration of quinolones, the tympanoplasty wound is far from sterile, which may impact healing outcomes.
- 22 June 2021
- Published by Wiley in The Laryngoscope
- Vol. 131 (10) , 2319-2322
Efficacy of Topical Epinephrine in Tympanoplasty
Objectives/Hypothesis To compare the hemostatic effects of commonly used concentrations of topical epinephrine in tympanoplasty. Study Design Prospective, randomized, controlled clinical trial. Methods Patients undergoing tympanoplasty were randomized to receive topical epinephrine at 1:1,000 or 1:10,000. With the investigators blinded, hemostasis was assessed with a modified Boezaart scale. Vasoconstriction was measured by laser Doppler. Blood pressure and pulse were tracked. Results Thirty patients, 4 to 84 years old, were studied, with 15 patients per group. Boezaart scores dropped a mean of 67% and 62% with 1:1,000 and 1:10,000, respectively (P = .44). Capillary blood flow decreased a mean of 50.4% and 50.9% with 1:1,000 and 1:10,000, respectively (P = .95). The mean change in heart rate and mean arterial pressure after topical epinephrine exposure were −4.9 and −0.73 beats per minute (P = .15), and −0.60 and −0.73 mmHg (P = .96) for 1:1,000 and 1:10,000 respectively. No adverse events occurred in either group. Conclusions Topical epinephrine at 1:10,000 has hemostatic efficacy comparable to 1:1,000 in tympanoplasty. Although both concentrations appear safe, use of topical epinephrine 1:10,000 should be considered over 1:1,000 to minimize the potential for adverse events. Level of Evidence 2 Laryngoscope, 2021
- 22 June 2021
- Published by Wiley in The Laryngoscope
- Vol. 131 (10) , 2319-2322
Efficacy of Topical Epinephrine in Tympanoplasty
Objectives/Hypothesis To compare the hemostatic effects of commonly used concentrations of topical epinephrine in tympanoplasty. Study Design Prospective, randomized, controlled clinical trial. Methods Patients undergoing tympanoplasty were randomized to receive topical epinephrine at 1:1,000 or 1:10,000. With the investigators blinded, hemostasis was assessed with a modified Boezaart scale. Vasoconstriction was measured by laser Doppler. Blood pressure and pulse were tracked. Results Thirty patients, 4 to 84 years old, were studied, with 15 patients per group. Boezaart scores dropped a mean of 67% and 62% with 1:1,000 and 1:10,000, respectively (P = .44). Capillary blood flow decreased a mean of 50.4% and 50.9% with 1:1,000 and 1:10,000, respectively (P = .95). The mean change in heart rate and mean arterial pressure after topical epinephrine exposure were −4.9 and −0.73 beats per minute (P = .15), and −0.60 and −0.73 mmHg (P = .96) for 1:1,000 and 1:10,000 respectively. No adverse events occurred in either group. Conclusions Topical epinephrine at 1:10,000 has hemostatic efficacy comparable to 1:1,000 in tympanoplasty. Although both concentrations appear safe, use of topical epinephrine 1:10,000 should be considered over 1:1,000 to minimize the potential for adverse events. Level of Evidence 2 Laryngoscope, 2021
- 1 October 2019
- Published by Wolters Kluwer Health in Otology & Neurotology
- Vol. 40 (9) , 1186-1193
Microbiome Analysis of Cholesteatoma by Gene Sequencing
Objective: To compare the microbial flora of cholesteatoma and normal middle ears using gene-based sequencing analysis.Study Design: Controlledex vivohuman study.Setting: Academic, tertiary medical center.Subjects and Methods: Brush, swab, and tissue samples were each taken from cholesteatoma matrix and uninvolved tissue in patients with previously untreated, acquired cholesteatoma (n = 19) or middle ear mucosa from patients undergoing cochlear implantation with no history of cholesteatoma or previous middle ear surgery (control; n = 12). DNA was isolated from specimens then 16S rRNA gene sequencing was performed.Results: There was no difference in microbial yield between the sampling methods. Cholesteatoma specimens had lower relative abundance of 14 bacterial species compared with controls includingAcidovorax sp.,Bacillus sp.,Masillia sp.,Moraxella osloensis,Phenylobacterium conjunctum,Sphingomonas sp., andStaphylococcus epidermidis(allp < 0.05).Alternariasp. were present on nearly all the specimens.Alternariasp. andCladosporium herbarum(bothp ≤ 0.05) were lower in the cholesteatoma compared with control group. There was no difference in the relative abundance of any bacteria or fungi between the cholesteatoma matrix and uninvolved middle ear mucosa.Conclusions: Microbiome of cholesteatoma matrix is largely similar to adjacent mucosa. This differs from healthy ears. Further study is needed to understand if middle ear microbiome may impact cholesteatoma pathogenesis or treatment.
- 1 October 2019
- Published by Wolters Kluwer Health in Otology & Neurotology
- Vol. 40 (9) , 1186-1193
Microbiome Analysis of Cholesteatoma by Gene Sequencing
Objective: To compare the microbial flora of cholesteatoma and normal middle ears using gene-based sequencing analysis.Study Design: Controlledex vivohuman study.Setting: Academic, tertiary medical center.Subjects and Methods: Brush, swab, and tissue samples were each taken from cholesteatoma matrix and uninvolved tissue in patients with previously untreated, acquired cholesteatoma (n = 19) or middle ear mucosa from patients undergoing cochlear implantation with no history of cholesteatoma or previous middle ear surgery (control; n = 12). DNA was isolated from specimens then 16S rRNA gene sequencing was performed.Results: There was no difference in microbial yield between the sampling methods. Cholesteatoma specimens had lower relative abundance of 14 bacterial species compared with controls includingAcidovorax sp.,Bacillus sp.,Masillia sp.,Moraxella osloensis,Phenylobacterium conjunctum,Sphingomonas sp., andStaphylococcus epidermidis(allp < 0.05).Alternariasp. were present on nearly all the specimens.Alternariasp. andCladosporium herbarum(bothp ≤ 0.05) were lower in the cholesteatoma compared with control group. There was no difference in the relative abundance of any bacteria or fungi between the cholesteatoma matrix and uninvolved middle ear mucosa.Conclusions: Microbiome of cholesteatoma matrix is largely similar to adjacent mucosa. This differs from healthy ears. Further study is needed to understand if middle ear microbiome may impact cholesteatoma pathogenesis or treatment.
- Open Access
- 29 October 2018
- Published by Wiley in Laryngoscope Investigative Otolaryngology
- Vol. 3 (6) , 492-495
Efficacy of common reagents for killing ticks in the ear canal
Objective: To determine if widely available solutions can effectively kill ticks that may be found in the human ear canal.Methods: This study was prospective, controlled and blinded animal study. Lone star ticks (Amblyomma americanum), both nymphal and adult, were submerged in one of four preparations (acetone, isopropyl alcohol 70%, ethanol 95%, or 4% lidocaine) in test tubes (n = 20 per group) for 20 minutes. Ticks were agitated by intermittent probing. Activity of the nymphal ticks was directly observed while those of the adult ticks was video‐recorded during the exposure period. Two blinded investigators viewed the videos of adult ticks and during the exposure period to determine the time until death (ie, movement cessation). Mortality was assessed immediately after exposure, and confirmed 24 and 48 hours after exposure.Results: Acetone killed ticks most rapidly (nymph mean time = 185.1 s; adult mean time = 562.9 s). Isopropyl alcohol 70% (nymphs, 328.9 s; adults, 1128.4 s) and ethanol 95% (nymphs, 294 s; adults, 1129.4 s) took longer to kill the ticks. All ticks treated with 4% lidocaine survived. These differences were significant (nymphs, P < .0001; adults, P < .0001).Conclusions: Acetone was the fastest acting and most effective reagent, followed by ethanol and isopropyl alcohol. These solutions may prove useful in otoacariasis with an intact tympanic membrane.Level of Evidence: N/A
- 29 October 2018
- Published by Wiley in Laryngoscope Investigative Otolaryngology
- Vol. 3 (6) , 492-495
Open AccessEfficacy of common reagents for killing ticks in the ear canal
Objective: To determine if widely available solutions can effectively kill ticks that may be found in the human ear canal.Methods: This study was prospective, controlled and blinded animal study. Lone star ticks (Amblyomma americanum), both nymphal and adult, were submerged in one of four preparations (acetone, isopropyl alcohol 70%, ethanol 95%, or 4% lidocaine) in test tubes (n = 20 per group) for 20 minutes. Ticks were agitated by intermittent probing. Activity of the nymphal ticks was directly observed while those of the adult ticks was video‐recorded during the exposure period. Two blinded investigators viewed the videos of adult ticks and during the exposure period to determine the time until death (ie, movement cessation). Mortality was assessed immediately after exposure, and confirmed 24 and 48 hours after exposure.Results: Acetone killed ticks most rapidly (nymph mean time = 185.1 s; adult mean time = 562.9 s). Isopropyl alcohol 70% (nymphs, 328.9 s; adults, 1128.4 s) and ethanol 95% (nymphs, 294 s; adults, 1129.4 s) took longer to kill the ticks. All ticks treated with 4% lidocaine survived. These differences were significant (nymphs, P < .0001; adults, P < .0001).Conclusions: Acetone was the fastest acting and most effective reagent, followed by ethanol and isopropyl alcohol. These solutions may prove useful in otoacariasis with an intact tympanic membrane.Level of Evidence: N/A
- 1 September 2015
- Published by Elsevier in Mitochondrion
- Vol. 24, S35
Assessing mitochondrial function in OC1 and PK1 cells treated with gentamicin and MitoQ
- 1 September 2015
- Published by Elsevier in Mitochondrion
- Vol. 24, S35
Assessing mitochondrial function in OC1 and PK1 cells treated with gentamicin and MitoQ